Literature DB >> 12169041

Oral bioavailability of desloratadine is unaffected by food.

Samir Gupta1, Christopher Banfield, Melton Affrime, Thomas Marbury, Desmond Padhi, Paul Glue.   

Abstract

OBJECTIVE: To determine the effect of coadministration of food on the bioavailability of oral desloratadine.
DESIGN: A randomised, open-label, single dose crossover study in which healthy adults received a single, oral dose of desloratadine 7.5mg, 50% greater than the recommended dose of 5mg, under fed or fasted conditions and were then crossed over to receive the other treatment regimen. PARTICIPANTS: 18 healthy volunteers (11 men, 7 women) aged from 18 to 43 (mean 29) years and weighing 54 to 104 (mean 76.4) kg were enrolled and completed this study. MAIN OUTCOME MEASURES: C(max), AUC(S) and AUC(infinity ).
RESULTS: Maximum mean plasma concentration (C(max)) was 3.53 microg/L in fed compared with 3.30 microg/L in fasted participants. Area under the plasma concentration-time curve from time 0 to time of final quantifiable sample (AUC(S)) mean values were 61.0 microg/L x h in fed and 61.9 microg/L x h in fasted participants. Fed individuals had mean AUC extrapolated to infinity (AUC(infinity )) of 62.5 microg/L x h compared with 63.5 microg/L x h in fasted participants. None of these differences between the fed and fasted state was statistically significant. The most frequently reported adverse event was headache. There were no statistically significant changes in ECG parameters.
CONCLUSION: The results of this study indicate that food has no effect on the oral bioavailability of a single oral dose of desloratadine 7.5mg.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12169041     DOI: 10.2165/00003088-200241001-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  5 in total

Review 1.  Enhancing patient compliance in the elderly. Role of packaging aids and monitoring.

Authors:  J A Cramer
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

2.  Preclinical pharmacology of desloratadine, a selective and nonsedating histamine H1 receptor antagonist. 1st communication: receptor selectivity, antihistaminic activity, and antiallergenic effects.

Authors:  W Kreutner; J A Hey; J Anthes; A Barnett; S Young; S Tozzi
Journal:  Arzneimittelforschung       Date:  2000-04

3.  A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability.

Authors:  D J Schuirmann
Journal:  J Pharmacokinet Biopharm       Date:  1987-12

Review 4.  Physiochemical and physiological mechanisms for the effects of food on drug absorption: the role of lipids and pH.

Authors:  W N Charman; C J Porter; S Mithani; J B Dressman
Journal:  J Pharm Sci       Date:  1997-03       Impact factor: 3.534

5.  Desloratadine demonstrates dose proportionality in healthy adults after single doses.

Authors:  Samir Gupta; Christopher Banfield; Melton Affrime; Aliceann Marco; Mitchell Cayen; Jerry Herron; Desmond Padhi
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

  5 in total
  7 in total

Review 1.  The safety and efficacy of desloratadine for the management of allergic disease.

Authors:  William E Berger
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 2.  Second-generation antihistamines: actions and efficacy in the management of allergic disorders.

Authors:  Larry K Golightly; Leon S Greos
Journal:  Drugs       Date:  2005       Impact factor: 9.546

3.  Exploring the Relationship of Drug BCS Classification, Food Effect, and Gastric pH-Dependent Drug Interactions.

Authors:  Katie Owens; Sophie Argon; Jingjing Yu; Xinning Yang; Fang Wu; Sue-Chih Lee; Wei-Jhe Sun; Anuradha Ramamoorthy; Lei Zhang; Isabelle Ragueneau-Majlessi
Journal:  AAPS J       Date:  2021-12-27       Impact factor: 4.009

4.  Effect of race and sex on single and multiple dose pharmacokinetics of desloratadine.

Authors:  Melton Affrime; Christopher Banfield; Samir Gupta; Albert Cohen; Tanya Boutros; Mohan Thonoor; Mitchell Cayen
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 5.  Desloratadine: an update of its efficacy in the management of allergic disorders.

Authors:  David Murdoch; Karen L Goa; Susan J Keam
Journal:  Drugs       Date:  2003       Impact factor: 9.546

6.  Prevalence of Desloratadine Slow-metabolizer Phenotype and Food-dependent Pharmacokinetics of Desloratadine in Healthy Chinese Volunteers.

Authors:  Ting Wang; Kun Zhang; Tingting Li; Lin He; Huiru Xie; Xuehua Jiang; Ling Wang
Journal:  Clin Drug Investig       Date:  2015-12       Impact factor: 2.859

7.  24-hour efficacy of once-daily desloratadine therapy in patients with seasonal allergic rhinitis [ISRCTN32042139].

Authors:  Luis M Salmun; Richard Lorber
Journal:  BMC Fam Pract       Date:  2002-08-05       Impact factor: 2.497

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.